Daly City, CA, United States of America

Chris A Buhr


Average Co-Inventor Count = 2.1

ph-index = 9

Forward Citations = 2,350(Granted Patents)


Company Filing History:


Years Active: 1993-2005

Loading Chart...
11 patents (USPTO):Explore Patents

Title: The Innovations of Chris A. Buhr: Pioneering Oligonucleotide Technologies

Introduction

Chris A. Buhr, an accomplished inventor based in Daly City, California, has made significant contributions to the field of oligonucleotide research. With a portfolio of 11 patents, his innovations are aimed at enhancing therapeutic applications through novel chemical compositions.

Latest Patents

Among his latest patents is the invention of modified oligonucleotides. These oligomers feature substituents at the 2' position, making them resistant to oligonucleases. This property allows for the derivatization of these molecules for the delivery of reagents or drugs, as well as for carrying labels or providing additional functional properties. Additionally, Buhr has developed nucleoside hydrogen phosphonodithioate diesters and their activated analogues. These novel compositions support the formation of internucleotide and internucleoside linkages, proving to be particularly beneficial in therapeutic applications, such as antiviral and anticancer agents. His methods for synthesizing these compounds and converting them to activated intermediates have added valuable tools to the arsenal of nucleic acid technology.

Career Highlights

Buhr's innovative journey includes significant tenures at notable companies, including Gilead Sciences, Inc. and Isis Pharmaceuticals, Inc. His work at these organizations has not only propelled his career but has also contributed to groundbreaking advancements in pharmaceutical applications.

Collaborations

Throughout his career, Chris A. Buhr has collaborated with esteemed professionals, including Mark D. Matteucci and Brian C. Froehler. These collaborations have likely facilitated the exchange of ideas and furthered research initiatives within the field of oligonucleotide technology.

Conclusion

With his extensive background in oligonucleotide innovations, Chris A. Buhr exemplifies the spirit of inventiveness that drives progress in biotechnology. His patents reflect a commitment to advancing healthcare solutions, ensuring that his work has a lasting impact on the industry and the patients it serves.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…